Overview

Study of CCNU (Lomustine) Plus Dasatinib in Recurrent Glioblastoma (GBM)

Status:
Terminated
Trial end date:
2011-05-01
Target enrollment:
Participant gender:
Summary
To determine whether dasatinib plus lomustine are effective for treatment of recurrent glioblastoma
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Bristol-Myers Squibb
Collaborator:
European Organisation for Research and Treatment of Cancer - EORTC
Treatments:
Dasatinib
Lomustine